The National Centre for Pharmacoeconomics backed public reimbursement while flagging the bill. A PwC study found one in five Irish consumers open to weight-loss drugs.
Recap by typeshit. Full story at Wansom AI.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
MedPage Today
She's screened for diabetes at a BMI of 23 but denied a GLP-1 until 30. She argues insurers should use ethnicity-adjusted thresholds that guidelines already publish.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
WADA's 2027 prohibited list brings new details on how peptides and GLP-1 drugs are treated in tested sport. Full breakdown at Men's Fitness.
Loading…